刘峥 谢春华 杨基鹏 田德伟 魏玮.乳腺癌患者血清内IL-6 和CCL-18表达及其与临床病理因素的关系[J].现代生物医学进展英文版,2016,16(4):759-762. |
乳腺癌患者血清内IL-6 和CCL-18表达及其与临床病理因素的关系 |
SerumIL-6 and CCL-18 Levels in Patients with Breast Cancer and TheirRelationship with Clinical Pathological Indexes |
|
DOI: |
中文关键词: 乳腺癌 IL-6 CCL-18 细胞因子 |
英文关键词: Brest cancer IL-6 CCL-18 Cytokine |
基金项目: |
|
Hits: 721 |
Download times: 0 |
中文摘要: |
目的:探究乳腺癌患者血清内白细胞介素-6(IL-6)和趋化因子配体-18(CCL-18)表达水平及其与临床病理因素的关系。方
法:本研究于2014 年4 月~2015 年4 月期间,选择我院收治31 例乳腺癌患者(乳腺癌组)、29 例良性肿瘤患者(良性肿瘤组)与
30 例健康体检者(对照组)为研究对象,采用酶联免疫吸附试验(ELISA)法测定所有研究对象的血清IL-6 与CCL-18 水平,采用
免疫组化法检测患者的临床病理参数。结果:乳腺癌组患者血清IL-6 和CCL-18 水平均显著高于良性肿瘤组和对照组,良性肿瘤
组血清IL-6 和CCL-18 水平高于对照组,差异均有统计学意义(P<0.05);血清IL-6S水平与雌激素受体(ER)、肿瘤增殖抗原
(Ki67)、肿瘤TNM 分期及淋巴转移存在关联(P<0.05),血清CCL-18 水平与Ki67 与肿瘤TNM 分期存在关联(P<0.05)。结论:
IL-6 和CCL-18 在乳腺癌患者内出现高表达,且均可预示患者肿瘤的发展恶化,影响预后。 |
英文摘要: |
Objective:To explore serum interleukin-6(IL-6) and chemokine C-C motif ligand-18(CCL-18) levels in patients with
breast cancer and their relationship with clinical pathological indexes.Methods:A total of 31 patients with breast cancer (breast cancer
group), 29 patients with benign tumor(benign tumor group) and 30 healthy people(control group), who were admitted to Zhuhai People's
Hospital from April 2014 to April 2015, were chosen as the research subjects. The serum levels of IL-6 and CCL-18 of all the subjects
were detected by enzyme-linked immunosorbent assay(ELISA) method and the clinical pathological indexes of breast cancer group were
detected by immunohistochemical method.Results:The serum IL-6 and CCL-18 levels in breast cancer group were significantly higher
than those in benign tumor group and control group, and the serumIL-6 and CCL-18 levels in benign tumor group were significant higher
than those in control group, the differences were statistically significant (P<0.05). Serum IL-6 level was related with estrogen receptor
(ER), antigens Ki67 (Ki67), TNM stage and the lymph node metastases (P<0.05), and serum CCL-18 level was related with Ki67 and
TNMstage (P<0.05).Conclusion:The serum IL-6 and CCL-18 levels in patients with breast cancer highly express, which indicates the
deterioration of tumor and adverse prognosis of the patients. |
View Full Text
View/Add Comment Download reader |
Close |